Error loading player: No playable sources found
VL21CEMAR1/SES108
Single Use Technologies - Are they sustainable?
Date
March 16, 2021
Explore related products in the following collection:
Single Use Technologies - Are they sustainable? | Over more than two decades, the pharmaceutical industry has increasingly adopted single-use technologies primarily to simplify manufacturing and seemingly to reduce cost; however, the need to reduce environmental burden has a huge impact on these facilities. This session will focus on single-use technologies for gene and cell therapy facilities, while considering the impact on sustainability.
Our first presenter will investigate the impact of single-use with respect to proper cleaning, disposal, and handling, and how it relates to vaccine production including Industry 4.0 and implementation of the 6R's.
Our second presenter will discuss the unique nature of Advanced Therapy Facilities including the advantages and disadvantages of single-use and modular clean room technology as well as flexible manufacturing for gene and cell therapies.
Our first presenter will investigate the impact of single-use with respect to proper cleaning, disposal, and handling, and how it relates to vaccine production including Industry 4.0 and implementation of the 6R's.
Our second presenter will discuss the unique nature of Advanced Therapy Facilities including the advantages and disadvantages of single-use and modular clean room technology as well as flexible manufacturing for gene and cell therapies.
Session Leader
Director of Sales and Business Development, GMP Systems Inc
Speakers
Strategic Solutions Leader, Arcadis
Corporate Research Fellow, Sartorius Stedim FMT SAS
Director, Project Farma
Exec. Director, Clinical Site Head, Tenaya Therapeutics
Related Products
Devices and Decontamination—Overcoming Challenges
Devices and Decontamination—Overcoming Challenges | Aseptic products are oftentimes a component part of a Combination Product. These aseptically filled present technical challenges that will be addressed in this session. Additionally, manufacturers are often tasked with utilizing legacy equipment…
Revision of EU GMPs Annex 1: What Impacts Can We Expect as an Industry?
Revision of EU GMPs Annex 1: What Impacts Can We Expect as an Industry? | 2020 saw the commenting of the draft Annex 1, which included many changes to the 2017 version. In this session, we will cover the commenting process both from the ISPE and the PHSS perspective…
Regulatory and Industry Panel
Regulatory and Industry Panel | The Regulatory and Industry Panel is one of the highlights of this conference. This session features questions and answers of the most daunting regulatory issues facing regulators and industry at this time…
Regulatory View on ATMPs and Make vs. Buy
Make vs. Buy in Gene and Cell Therapy and the update on PIC/S Annex 2A Revision for ATMPs will be the topics during this ATMP Session…
